Longview Acquisition II PE Ratio 2021-2022 | LGV

Longview Acquisition II PE ratio as of November 25, 2024 is 0.00.

Current and historical p/e ratio for Longview Acquisition II (LGV) from 2021 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Longview Acquisition II PE Ratio 2021-2022 | LGV

Current and historical p/e ratio for Longview Acquisition II (LGV) from 2021 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$196.3B
Intuitive Surgical (ISRG)$195.1B
Alcon (ALC)$42.4B
Edwards Lifesciences (EW)$41.6B
IQVIA Holdings (IQV)$36.6B
IDEXX Laboratories (IDXX)$34.2B
DexCom (DXCM)$28.4B
Waters (WAT)$22.2B
STERIS (STE)$21.2B
SONOVA HOLDING (SONVY)$20.8B
Hologic (HOLX)$18.3B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.9B
Globus Medical (GMED)$11.5B
Penumbra (PEN)$9.4B
Masimo (MASI)$9.3B
Teleflex (TFX)$8.9B
Glaukos (GKOS)$7.9B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.6B
Veracyte (VCYT)$3.1B
Inari Medical (NARI)$2.9B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.6B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.8B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.4B